SG11201702558VA - Treatment of cancer with immune stimulators - Google Patents

Treatment of cancer with immune stimulators

Info

Publication number: SG11201702558VA
Authority: SG; Singapore
Prior art keywords: cancer; treatment; immune stimulators; stimulators; immune
Prior art date: 2014-10-21

Application number

SG11201702558VA

Other languages

English (en)

Inventor

Robert S King

Cynthia Tuthill

Friedhelm Blobel

Original Assignee

Sciclone Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-21

Filing date

2015-10-21

Publication date

2017-05-30

2015-10-21 Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc

2017-05-30 Publication of SG11201702558VA publication Critical patent/SG11201702558VA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

SG11201702558VA 2014-10-21 2015-10-21 Treatment of cancer with immune stimulators SG11201702558VA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462066862P	2014-10-21	2014-10-21
US201562215433P	2015-09-08	2015-09-08
PCT/US2015/056609 WO2016064969A1 (en)	2014-10-21	2015-10-21	Treatment of cancer with immune stimulators

Publications (1)

Publication Number	Publication Date
SG11201702558VA true SG11201702558VA (en)	2017-05-30

Family

ID=55748164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201702558VA SG11201702558VA (en)	2014-10-21	2015-10-21	Treatment of cancer with immune stimulators

Country Status (16)

Country	Link
US (4)	US9724395B2 (ja)
EP (2)	EP3209321B1 (ja)
JP (2)	JP6821560B2 (ja)
KR (1)	KR102589557B1 (ja)
CN (2)	CN107148279B (ja)
AU (1)	AU2015335979B2 (ja)
BR (1)	BR112017007817A2 (ja)
CA (1)	CA2962451C (ja)
ES (1)	ES2882080T3 (ja)
IL (1)	IL251761B (ja)
MX (1)	MX2017005134A (ja)
RU (2)	RU2740288C2 (ja)
SG (1)	SG11201702558VA (ja)
TW (2)	TWI683667B (ja)
WO (1)	WO2016064969A1 (ja)
ZA (1)	ZA201702111B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102589557B1 (ko)	2014-10-21	2023-10-16	시클론 파마수티컬 인터내셔널 리미티드	면역 자극인자를 이용한 암의 치료
SG11201803080YA (en) *	2015-10-21	2018-05-30	Teclison Ltd	Compositions and methods for immune-mediated cancer therapy
WO2018138682A1 (en) *	2017-01-26	2018-08-02	Immune Therapeutics	Methods and compositions useful for treating cancer
CN109793891A (zh) *	2017-11-17	2019-05-24	韩震	多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
EP3747433A4 (en) *	2018-02-02	2021-12-22	Cafa Therapeutics Limited	CELLULAR IMMUNOTHERAPY ASSOCIATION
WO2020130300A1 (ko)	2018-12-21	2020-06-25	한미약품 주식회사	신규 면역 억제 인터루킨 2
IL295826A (en)	2020-03-31	2022-10-01	Hanmi Pharm Ind Co Ltd	Novel il-2 analogs that stimulate the immune system
CN112023027B (zh) *	2020-07-21	2023-03-14	广东海洋大学	胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物
CN111821424B (zh) *	2020-07-21	2023-03-31	广东海洋大学深圳研究院	胸腺素及其衍生物的应用和治疗抑郁症的药物
US20240009317A1 (en)	2021-03-31	2024-01-11	Hanmi Pharm. Co., Ltd.	Novel conjugate of immune-stimulating il-2 analog and preparation method thereof
WO2023069727A1 (en) *	2021-10-21	2023-04-27	Edison Oncology	Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
DE2604845A1 (de)	1976-02-07	1977-08-18	Knoll Ag	Neue piperazinderivate
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AR036993A1 (es)	2001-04-02	2004-10-20	Wyeth Corp	Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
UA80957C2 (en) *	2001-11-01	2007-11-26	Sciclone Pharmaceuticals Inc	Method of administering a thymosin alpha 1 peptide
CN101072582B (zh) *	2004-12-06	2012-06-27	赛生制药有限公司	作为癌症疫苗佐剂的α胸腺肽
EP2161336B2 (en) *	2005-05-09	2017-03-29	ONO Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2626859A1 (en)	2005-11-08	2007-05-18	Medarex, Inc.	Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
CA2657821A1 (en)	2006-07-21	2008-01-24	Gilead Sciences, Inc.	Aza-peptide protease inhibitors
US20080300166A1 (en) *	2007-06-01	2008-12-04	Sciclone Pharmaceuticals, Inc.	Treatment of Melanoma with Alpha Thymosin Peptides
AR067412A1 (es)	2007-07-06	2009-10-07	Gilead Sciences Inc	Moduladores de propiedades farmaceuticas de productos terapeuticos
US20090021740A1 (en) *	2007-07-17	2009-01-22	Chung Yuan Christian University	Optical sensor and method for measuring blood gas
WO2009075813A1 (en) *	2007-12-12	2009-06-18	Sciclone Pharmaceuticals, Inc.	Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
EP2240194A4 (en) *	2007-12-13	2011-12-21	Sciclone Pharmaceuticals Inc	TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES IN COMBINATION WITH A KINASE INHIBITOR
CA2708168A1 (en) *	2007-12-14	2009-06-25	Sciclone Pharmaceuticals, Inc.	Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
JP5945096B2 (ja)	2008-07-04	2016-07-05	小野薬品工業株式会社	抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
AU2009290543B2 (en)	2008-09-12	2015-09-03	Oxford University Innovation Limited	PD-1 specific antibodies and uses thereof
WO2010036959A2 (en)	2008-09-26	2010-04-01	Dana-Farber Cancer Institute	Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
US8741295B2 (en)	2009-02-09	2014-06-03	Universite De La Mediterranee	PD-1 antibodies and PD-L1 antibodies and uses thereof
CN101591397A (zh) *	2009-07-01	2009-12-02	石继红	长效胸腺素α1的重组表达及其用途
US20140213506A1 (en) *	2011-02-09	2014-07-31	Cynthia W. TUTHILL	Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
KR101970025B1 (ko)	2011-04-20	2019-04-17	메디뮨 엘엘씨	Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP5790345B2 (ja) *	2011-09-07	2015-10-07	株式会社リコー	画像処理装置、画像処理方法、プログラムおよび画像処理システム
PT3381942T (pt) *	2012-08-30	2021-05-24	Amgen Inc	Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário
KR102589557B1 (ko)	2014-10-21	2023-10-16	시클론 파마수티컬 인터내셔널 리미티드	면역 자극인자를 이용한 암의 치료

2015
- 2015-10-21 KR KR1020177011825A patent/KR102589557B1/ko active IP Right Grant
- 2015-10-21 JP JP2017519663A patent/JP6821560B2/ja active Active
- 2015-10-21 MX MX2017005134A patent/MX2017005134A/es unknown
- 2015-10-21 RU RU2017117194A patent/RU2740288C2/ru active
- 2015-10-21 SG SG11201702558VA patent/SG11201702558VA/en unknown
- 2015-10-21 ES ES15852092T patent/ES2882080T3/es active Active
- 2015-10-21 EP EP15852092.4A patent/EP3209321B1/en active Active
- 2015-10-21 TW TW104134583A patent/TWI683667B/zh active
- 2015-10-21 EP EP21178724.7A patent/EP3943101A1/en active Pending
- 2015-10-21 WO PCT/US2015/056609 patent/WO2016064969A1/en active Application Filing
- 2015-10-21 RU RU2020142556A patent/RU2020142556A/ru unknown
- 2015-10-21 TW TW108147603A patent/TWI749433B/zh active
- 2015-10-21 CA CA2962451A patent/CA2962451C/en active Active
- 2015-10-21 AU AU2015335979A patent/AU2015335979B2/en active Active
- 2015-10-21 CN CN201580057457.9A patent/CN107148279B/zh active Active
- 2015-10-21 BR BR112017007817A patent/BR112017007817A2/pt active Search and Examination
- 2015-10-21 US US14/918,675 patent/US9724395B2/en active Active
- 2015-10-21 CN CN202111207032.5A patent/CN113855806A/zh active Pending
2017
- 2017-03-27 ZA ZA2017/02111A patent/ZA201702111B/en unknown
- 2017-04-18 IL IL251761A patent/IL251761B/en active IP Right Grant
- 2017-07-05 US US15/641,550 patent/US20180161399A1/en not_active Abandoned
2020
- 2020-01-07 US US16/736,211 patent/US11571465B2/en active Active
2021
- 2021-01-06 JP JP2021000764A patent/JP7175334B2/ja active Active
2022
- 2022-12-12 US US18/064,793 patent/US20230285513A1/en active Pending

Also Published As

Publication number	Publication date
CA2962451A1 (en)	2016-04-28
TW202034946A (zh)	2020-10-01
ZA201702111B (en)	2019-06-26
US11571465B2 (en)	2023-02-07
US9724395B2 (en)	2017-08-08
WO2016064969A1 (en)	2016-04-28
RU2017117194A3 (ja)	2019-04-09
EP3209321A1 (en)	2017-08-30
EP3943101A1 (en)	2022-01-26
EP3209321A4 (en)	2018-10-31
JP2021088557A (ja)	2021-06-10
TW201615209A (zh)	2016-05-01
AU2015335979B2 (en)	2021-05-20
JP7175334B2 (ja)	2022-11-18
MX2017005134A (es)	2018-02-12
TWI749433B (zh)	2021-12-11
KR20170070091A (ko)	2017-06-21
RU2017117194A (ru)	2018-11-22
JP6821560B2 (ja)	2021-01-27
RU2020142556A (ru)	2021-02-12
US20230285513A1 (en)	2023-09-14
IL251761B (en)	2020-09-30
US20160106812A1 (en)	2016-04-21
US20180161399A1 (en)	2018-06-14
KR102589557B1 (ko)	2023-10-16
US20200289618A1 (en)	2020-09-17
BR112017007817A2 (pt)	2017-12-19
CA2962451C (en)	2023-01-17
IL251761A0 (en)	2017-06-29
JP2018501192A (ja)	2018-01-18
CN113855806A (zh)	2021-12-31
ES2882080T3 (es)	2021-12-01
CN107148279B (zh)	2021-09-03
CN107148279A (zh)	2017-09-08
EP3209321B1 (en)	2021-06-23
RU2740288C2 (ru)	2021-01-12
TWI683667B (zh)	2020-02-01
AU2015335979A1 (en)	2017-04-20

Publication	Publication Date	Title
IL250677B (en)	2021-03-25	Cancer treatment using anti-nkg2a agents
FI3851537T3 (fi)	2024-03-21	Hyperbilirubinemian hoito
GB201701673D0 (en)	2017-03-15	Methods of well treatment
IL251761A0 (en)	2017-06-29	Cancer treatment with immune system stimulants
IL261959A (en)	2018-10-31	Cancer treatment with tg02
RS61536B1 (sr)	2021-04-29	Kombinacije fgfr- i cmet-inhibitora za lečenje kancera
HK1231561A1 (zh)	2017-12-22	癌症治療
HK1231386A1 (zh)	2017-12-22	免疫疾病的治療
IL263835A (en)	2019-02-03	Exosome-guided treatment of cancer
GB201416832D0 (en)	2014-11-05	Methods of treatment
HK1249866A1 (zh)	2018-11-16	用他塞利昔布進行治療的方法
GB201409363D0 (en)	2014-07-09	Skin cancer treatment
GB201408297D0 (en)	2014-06-25	Treatment of cancer
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201417456D0 (en)	2014-11-19	Treatment of cancer
GB201407837D0 (en)	2014-06-18	Methods of cancer therapy
GB201622214D0 (en)	2017-02-08	treatment of cancer
GB201409362D0 (en)	2014-07-09	Treatment of cancer
GB201604621D0 (en)	2016-05-04	Treatment of cancer
GB201604293D0 (en)	2016-04-27	Treatment of cancer
GB201405449D0 (en)	2014-05-07	Treatment of cancer
GB201405075D0 (en)	2014-05-07	Treatment of cancer
GB201512723D0 (en)	2015-08-26	Treatment of cancer
PT3851537T (pt)	2024-03-06	Tratamento da hiperbilirrubinemia
GB201417465D0 (en)	2014-11-19	Treatment of cancers